Copyright Reports & Markets. All rights reserved.

Global Psoriasis Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Psoriasis Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Psoriasis Drug Market Size Growth Rate by Product
      • 1.4.2 External Use
      • 1.4.3 Oral
      • 1.4.4 Injection
    • 1.5 Market by End User
      • 1.5.1 Global Psoriasis Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Drugs Store
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Psoriasis Drug Market Size
      • 2.1.1 Global Psoriasis Drug Revenue 2014-2025
      • 2.1.2 Global Psoriasis Drug Sales 2014-2025
    • 2.2 Psoriasis Drug Growth Rate by Regions
      • 2.2.1 Global Psoriasis Drug Sales by Regions
      • 2.2.2 Global Psoriasis Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Psoriasis Drug Sales by Manufacturers
      • 3.1.1 Psoriasis Drug Sales by Manufacturers
      • 3.1.2 Psoriasis Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Psoriasis Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Psoriasis Drug Revenue by Manufacturers
      • 3.2.1 Psoriasis Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Psoriasis Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Psoriasis Drug Price by Manufacturers
    • 3.4 Psoriasis Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Psoriasis Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Psoriasis Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Psoriasis Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Psoriasis Drug Sales by Product
    • 4.2 Global Psoriasis Drug Revenue by Product
    • 4.3 Psoriasis Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Psoriasis Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Psoriasis Drug by Countries
      • 6.1.1 North America Psoriasis Drug Sales by Countries
      • 6.1.2 North America Psoriasis Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Psoriasis Drug by Product
    • 6.3 North America Psoriasis Drug by End User

    7 Europe

    • 7.1 Europe Psoriasis Drug by Countries
      • 7.1.1 Europe Psoriasis Drug Sales by Countries
      • 7.1.2 Europe Psoriasis Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Psoriasis Drug by Product
    • 7.3 Europe Psoriasis Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Psoriasis Drug by Countries
      • 8.1.1 Asia Pacific Psoriasis Drug Sales by Countries
      • 8.1.2 Asia Pacific Psoriasis Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Psoriasis Drug by Product
    • 8.3 Asia Pacific Psoriasis Drug by End User

    9 Central & South America

    • 9.1 Central & South America Psoriasis Drug by Countries
      • 9.1.1 Central & South America Psoriasis Drug Sales by Countries
      • 9.1.2 Central & South America Psoriasis Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Psoriasis Drug by Product
    • 9.3 Central & South America Psoriasis Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Psoriasis Drug by Countries
      • 10.1.1 Middle East and Africa Psoriasis Drug Sales by Countries
      • 10.1.2 Middle East and Africa Psoriasis Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Psoriasis Drug by Product
    • 10.3 Middle East and Africa Psoriasis Drug by End User

    11 Company Profiles

    • 11.1 AbbVie
      • 11.1.1 AbbVie Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AbbVie Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AbbVie Psoriasis Drug Products Offered
      • 11.1.5 AbbVie Recent Development
    • 11.2 Johnson & Johnson
      • 11.2.1 Johnson & Johnson Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Johnson & Johnson Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Johnson & Johnson Psoriasis Drug Products Offered
      • 11.2.5 Johnson & Johnson Recent Development
    • 11.3 Bayer
      • 11.3.1 Bayer Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Bayer Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Bayer Psoriasis Drug Products Offered
      • 11.3.5 Bayer Recent Development
    • 11.4 Galderma
      • 11.4.1 Galderma Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Galderma Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Galderma Psoriasis Drug Products Offered
      • 11.4.5 Galderma Recent Development
    • 11.5 Bristol-Myers Squibb
      • 11.5.1 Bristol-Myers Squibb Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Bristol-Myers Squibb Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Bristol-Myers Squibb Psoriasis Drug Products Offered
      • 11.5.5 Bristol-Myers Squibb Recent Development
    • 11.6 Novartis
      • 11.6.1 Novartis Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Novartis Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Novartis Psoriasis Drug Products Offered
      • 11.6.5 Novartis Recent Development
    • 11.7 Pfizer
      • 11.7.1 Pfizer Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Pfizer Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Pfizer Psoriasis Drug Products Offered
      • 11.7.5 Pfizer Recent Development
    • 11.8 Merz Pharma
      • 11.8.1 Merz Pharma Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Merz Pharma Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Merz Pharma Psoriasis Drug Products Offered
      • 11.8.5 Merz Pharma Recent Development
    • 11.9 Valeant
      • 11.9.1 Valeant Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Valeant Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Valeant Psoriasis Drug Products Offered
      • 11.9.5 Valeant Recent Development
    • 11.10 LEO Pharma
      • 11.10.1 LEO Pharma Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 LEO Pharma Psoriasis Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 LEO Pharma Psoriasis Drug Products Offered
      • 11.10.5 LEO Pharma Recent Development
    • 11.11 GlaxoSmithKline

    12 Future Forecast

    • 12.1 Psoriasis Drug Market Forecast by Regions
      • 12.1.1 Global Psoriasis Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Psoriasis Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Psoriasis Drug Market Forecast by Product
      • 12.2.1 Global Psoriasis Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Psoriasis Drug Revenue Forecast by Product 2019-2025
    • 12.3 Psoriasis Drug Market Forecast by End User
    • 12.4 North America Psoriasis Drug Forecast
    • 12.5 Europe Psoriasis Drug Forecast
    • 12.6 Asia Pacific Psoriasis Drug Forecast
    • 12.7 Central & South America Psoriasis Drug Forecast
    • 12.8 Middle East and Africa Psoriasis Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Psoriasis Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Psoriasis is a long-lasting autoimmune disease which is characterized by patches of abnormal skin.
      The global Psoriasis Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Psoriasis Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Psoriasis Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Psoriasis Drug in these regions.
      This research report categorizes the global Psoriasis Drug market by top players/brands, region, type and end user. This report also studies the global Psoriasis Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AbbVie
      Johnson & Johnson
      Bayer
      Galderma
      Bristol-Myers Squibb
      Novartis
      Pfizer
      Merz Pharma
      Valeant
      LEO Pharma
      GlaxoSmithKline

      Market size by Product
      External Use
      Oral
      Injection
      Market size by End User
      Hospital
      Drugs Store

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Psoriasis Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Psoriasis Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Psoriasis Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Psoriasis Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Psoriasis Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Psoriasis Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now